ACTRN12619000583145: A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion |
|
|
| Withdrawn | 2 | 40 | | | Australia New Zealand Gynaecological Oncology Group , Australia New Zealand Gynaecological Oncology Group | High Grade Serous Ovarian Cancer, Carcinosarcoma | | | | |
PRECISE, NCT03933761: Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy |
|
|
| Withdrawn | 2 | 0 | NA | Pamiparib, BGB-290 | Australia New Zealand Gynaecological Oncology Group, BeiGene | Ovarian Cancer, Carcinosarcoma | 08/21 | 08/21 | | |
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer |
|
|
| Recruiting | 1/2 | 38 | RoW | Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor | Sun Yat-sen University, Hutchmed | Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer | 08/24 | 08/25 | | |
